

Project Data Sphere and Qure.ai Combine Big Pharma Insights with Deep AI to Drive Cancer Care Forward

The partnership will focus on advancing cancer research using AI.

CARY, NORTH CAROLINA, UNITED STATES, January 16, 2024

/EINPresswire.com/ -- In a pivotal stride toward advancing cancer care, [Qure.ai](#), a leader in artificial intelligence (AI) solutions for medical imaging, and [Project Data Sphere](#)[®], a nonprofit initiative of the CEO Roundtable on Cancer, have announced their partnership to augment tumor assessments using AI-enabled solutions for clinical trials and cancer care. The collaboration aims to increase efficiency and consistency in evaluating the effectiveness of cancer treatments, ultimately improving the quality of care for patients.

The focus of this collaboration is autoRECIST, a product of Project Data Sphere's Images and Algorithms program. The program, initiated in consultation with the U.S. Food and Drug Administration, includes

stakeholders and experts from across the pharmaceutical industry and academia. In collaboration with Qure.ai, autoRECIST will address the critical need for automating and standardizing tumor response assessments in medical imaging to enhance cancer treatment and research. Rooted in current imaging guidelines, this AI clinical tool will aid radiologists in the detection, selection, measuring and tracking of lesions using defined criteria.

The logo for Qure.ai, featuring the text "qure.ai" in a stylized, orange-red font on a dark blue background with faint geometric patterns.

autoRECIST can improve clinical trials and cancer treatments through:

- Enhanced efficiency and improved accuracy through the automation of analyzing medical images (such as CT scans) and reducing variability when measuring tumor size and changes over time.
- Faster decision-making in the assessment of tumor response, which enables researchers and clinicians to quickly determine if a treatment is effective or if changes in care are required.

This collaboration enables the sharing of unique insights, advanced methodologies and access to a broader network of industry leaders, further enriching the development of the autoRECIST solution.

“We are excited to enter into this collaboration with Qure to deliver tools that will streamline imaging-based tumor burden measurements, an important part of both clinical trials and routine care for cancer patients,” said Jon McDunn, PhD, president of Project Data Sphere. “The autoRECIST program holds the promise of improving these processes and accelerating the delivery of lifesaving treatments to patients. We are very excited to be working with Qure.ai on this important project.”

“Collaborating with Project Data Sphere marks a pivotal moment in the evolution of cancer treatment, harnessing the transformative power of artificial intelligence,” said Prashant Warier, CEO and cofounder of Qure.ai. “Our development of autoRECIST is testament to our unwavering commitment to combating cancer. This groundbreaking AI innovation is set to revolutionize the evaluation of treatment efficacy in cancer patients. With a resolute focus on early detection, we’re leveraging our data science expertise to significantly advance clinical trial methodologies, ultimately changing the landscape of cancer care.”

This collaboration signifies a concerted effort by Qure.ai and Project Data Sphere to make substantial advancements in cancer care and elevate patient outcomes. The integration of AI technology into the evaluation process holds the potential to reshape the landscape of cancer clinical trials and generate more effective treatments for those affected by cancer.

About Project Data Sphere

Project Data Sphere (PDS) is an independent initiative of the CEO Roundtable on Cancer, a nonprofit organization founded to develop and implement initiatives that reduce the risk of cancer, enable early diagnosis, facilitate access to the best available treatments, and hasten the discovery of novel and more effective anti-cancer therapies. In addition to operating an open-access data-sharing platform, PDS manages research programs that explore leading issues in oncology using machine learning tools and big data analytics. For more information, visit www.projectdatasphere.org.

About Qure.ai

Qure.ai is a health tech company that uses deep learning and Artificial Intelligence (AI) tools to make healthcare more accessible and affordable to patients around the world in medical imaging & care coordination. Our technology fulfills a pertinent, unmet need in the radiology industry. With the aid of tools like those developed by Qure.ai, which work via a sophisticated set of algorithms that can instantly evaluate scans to prioritize actionable patient cases quickly, radiologists can focus their time and advanced skill sets on the most pressing diagnoses.

Mark Slagle

CEO Roundtable on Cancer

+1 919-360-7343

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/681657843>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.